Compare ASTE & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTE | CGEM |
|---|---|---|
| Founded | 1972 | 2016 |
| Country | United States | United States |
| Employees | 4468 | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 904.7M |
| IPO Year | 2003 | 2020 |
| Metric | ASTE | CGEM |
|---|---|---|
| Price | $48.69 | $13.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $66.00 | $30.13 |
| AVG Volume (30 Days) | 217.2K | ★ 881.8K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | ★ 784.21 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.72 | N/A |
| Revenue Next Year | $5.44 | $5.20 |
| P/E Ratio | $809.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.83 | $5.68 |
| 52 Week High | $65.69 | $16.74 |
| Indicator | ASTE | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 42.75 |
| Support Level | $47.69 | $12.41 |
| Resistance Level | $49.18 | $16.21 |
| Average True Range (ATR) | 2.31 | 0.94 |
| MACD | -0.63 | -0.16 |
| Stochastic Oscillator | 13.73 | 11.57 |
Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. The company has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.